In recent trading, shares of Maravai LifeSciences Holdings Inc (MRVI) have surpassed the average 12-month target price set by analysts, currently trading at $7.65 per share, above the average target of $7.42. There are a total of six analyst targets for MRVI, varying from a low of $6.50 to a high of $8.00, with a standard deviation of $0.664.
Currently, five analysts rate MRVI as a Strong Buy while five have rated it as Hold, with no analysts assigning a Buy, Sell, or Strong Sell rating. The average rating for the stock is 2.0, indicating strong buy sentiment among the analysts, which reflects a shift in outlook from previous months. This data is based on Zacks Investment Research.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
